Methods for determining personalized treatment compositions for prostate cancer and breast cancer
AssigneeCaldera Health Limited
InventorsJames D. Watson, Richard Llewellyn Sydney Forster
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a cancer, such as prostate or breast cancer, in a patient wherein the treatment composition includes administering a combination of at least two components selected from two different classes of compounds. Methods for treating a patient using the selected treatment composition are also provided, together with methods for monitoring the efficacy of the treatment composition during a treatment period.
Claims15
A method for determining the efficacy of a candidate anti-prostate cancer therapy for a patient diagnosed with prostate cancer wherein the candidate anti-prostate cancer therapy comprises an immune cell activating agent and an antigen display enhancing agent that is able to stimulate or enhance the presentation of a cancer-specific antigen on the surface of prostate cancer cells, the method comprising:
- (a) incubating immune cells obtained from the patient with the immune cell activating agent to provide activated immune cells;
- (b) incubating prostate cancer cells from an established prostate cancer cell line with the antigen display enhancing agent, thereby providing treated prostate cancer cells;
- (c) contacting the activated immune cells with the treated prostate cancer cells;
- and
- (d) determining the ability of the activated immune cells to kill the treated prostate cancer cells,
- wherein the ability of the activated immune cells to kill the treated prostate cancer cells is indicative of the efficacy of the candidate anti-prostate cancer therapy.
A method for monitoring the efficacy of an anti-prostate cancer therapy in a patient diagnosed with prostate cancer, wherein the anti-prostate cancer therapy comprises an immune cell activating agent and an antigen display enhancing agent that is able to stimulate or enhance the presentation of a cancer-specific antigen on the surface of prostate cancer cells, the method comprising:
- (a) incubating a first plurality of immune cells obtained from the patient prior to treatment with the immune cell activating agent to provide activated immune cells;
- (b) incubating prostate cancer cells from an established prostate cancer cell line with the antigen display enhancing agent, thereby providing treated prostate state cancer cells;
- (c) contacting the activated immune cells with the treated prostate cancer cells and determining the ability of the activated immune cells to kill the treated prostate cancer cells;
- and
- (d) repeating steps (b)-(c) with a second plurality of immune cells obtained from the patient at a subsequent time interval following administration of the anti-prostate cancer therapy,
- wherein a reduction in the ability of activated immune cells prepared from the second plurality of immune cells to kill the treated prostate cancer cells compared to the ability of activated immune cells prepared from the first plurality of immune cells to kill the treated prostate cancer cells is indicative of a reduction in the efficacy of the anti-prostate cancer therapy.
Dependencies are inferred from the claim text.